Xilio Therapeutics (XLO) Projected to Post Earnings on Monday

Xilio Therapeutics (NASDAQ:XLO) will likely be posting its quarterly earnings results before the market opens on Monday, April 7th. Analysts expect Xilio Therapeutics to post earnings of ($0.22) per share for the quarter.

Xilio Therapeutics (NASDAQ:XLO) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.02. The business had revenue of $1.72 million during the quarter, compared to the consensus estimate of $2.26 million. On average, analysts expect Xilio Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Xilio Therapeutics Stock Down 2.9 %

Shares of NASDAQ XLO opened at $0.68 on Friday. The firm’s 50-day simple moving average is $0.84 and its 200 day simple moving average is $0.93. Xilio Therapeutics has a fifty-two week low of $0.63 and a fifty-two week high of $1.70. The stock has a market cap of $35.19 million, a P/E ratio of -0.40 and a beta of -0.25.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.